AR114911A1 - Conjugados peptídicos de tlr7 - Google Patents
Conjugados peptídicos de tlr7Info
- Publication number
- AR114911A1 AR114911A1 ARP190101500A ARP190101500A AR114911A1 AR 114911 A1 AR114911 A1 AR 114911A1 AR P190101500 A ARP190101500 A AR P190101500A AR P190101500 A ARP190101500 A AR P190101500A AR 114911 A1 AR114911 A1 AR 114911A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptide
- tlr7
- conjugates
- vaccine
- peptidic conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Una clase de conjugados peptídicos derivados de pirimidina que tienen propiedades inmunomoduladoras mejoradas. Más específicamente el conjugado peptídico contiene un agonista de TLR7 y aumenta el efecto biológico del péptido al que está acoplado, incrementando la inmunogenicidad, y/o disminuyendo la dosis eficaz del péptido. En algunas formas de realización, el péptido es un antígeno, una vacuna, una vacuna neoantigénica basada en péptido, o un epitope.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862680332P | 2018-06-04 | 2018-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114911A1 true AR114911A1 (es) | 2020-10-28 |
Family
ID=67384303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101500A AR114911A1 (es) | 2018-06-04 | 2019-06-03 | Conjugados peptídicos de tlr7 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210228713A1 (es) |
EP (1) | EP3801628A1 (es) |
JP (1) | JP7339285B2 (es) |
CN (1) | CN112512590A (es) |
AR (1) | AR114911A1 (es) |
TW (1) | TW202015725A (es) |
WO (1) | WO2019236469A1 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806352A (en) | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
DE3768232D1 (de) * | 1986-12-19 | 1991-04-04 | Duphar Int Res | Dimethyldioctadecylammoniumbromid enthaltende stabilisierte adjuvanssuspension. |
DE3875762T2 (de) | 1987-03-17 | 1993-05-13 | Akzo Nv | Adjuvanzienmischung. |
PE20091236A1 (es) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
ES2458355T3 (es) * | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorción de inmunopotenciadores sobre sales metálicas insolubles |
US10010616B2 (en) * | 2011-01-28 | 2018-07-03 | Purdue Research Foundation | Immunogenic compositions and reagents for preparing |
JP7071392B2 (ja) * | 2016-12-05 | 2022-05-18 | アプロス セラピューティクス, インコーポレイテッド | 酸性基を含有するピリミジン化合物 |
-
2019
- 2019-06-03 US US15/734,922 patent/US20210228713A1/en active Pending
- 2019-06-03 TW TW108119117A patent/TW202015725A/zh unknown
- 2019-06-03 CN CN201980050014.5A patent/CN112512590A/zh active Pending
- 2019-06-03 AR ARP190101500A patent/AR114911A1/es unknown
- 2019-06-03 EP EP19742259.5A patent/EP3801628A1/en active Pending
- 2019-06-03 JP JP2020567229A patent/JP7339285B2/ja active Active
- 2019-06-03 WO PCT/US2019/035194 patent/WO2019236469A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP7339285B2 (ja) | 2023-09-05 |
US20210228713A1 (en) | 2021-07-29 |
WO2019236469A1 (en) | 2019-12-12 |
EP3801628A1 (en) | 2021-04-14 |
JP2021525773A (ja) | 2021-09-27 |
CN112512590A (zh) | 2021-03-16 |
TW202015725A (zh) | 2020-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122953T1 (el) | Ενα καινοτομο συμπλοκο που περιλαμβανει ενα κυτταροδιεισδυτικο πεπτιδιο, ενα φορτιο και εναν tlr πεπτιδικο αγωνιστη για την αντιμετωπιση του ορθοκολικου καρκινου | |
DOP2023000187A (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
CL2023002252A1 (es) | Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista | |
MX2020004543A (es) | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. | |
CL2019003805A1 (es) | Composiciones inmunógenas de senecavirus a y métodos de éstas. | |
CO2019011640A2 (es) | Métodos y composiciones para la reducción de la inmunogenicidad | |
CY1125104T1 (el) | Συνθεσεις φλαγελλινης entrecoccus για χρηση στη θεραπεια | |
AR100768A1 (es) | Método para disminuir la inmunogenicidad de proteínas y péptidos | |
CO6551750A2 (es) | Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio | |
PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
EA202090049A1 (ru) | Поксвирусные векторы, кодирующие антигены вич, и способы их применения | |
MX2015016627A (es) | Vacuna para la malaria. | |
AR101814A1 (es) | Partícula de tipo virus flavivirus | |
EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
CL2022000774A1 (es) | Vacunas para vhb y métodos de tratamiento de vhb | |
CL2007000526A1 (es) | Antigeno vacunal quimerico contra el virus de la influenza aviar, ia, que contiene el segmento extracelular de la hemaglutinina de la envoltura del virus de ia y el segmento extracelular de la proteina cd154; y composicion que lo comprende. | |
CY1117854T1 (el) | Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση | |
UY35418A (es) | Vacuna que proporciona protección frente a diferentes Picornavirus humanos. | |
CL2021001256A1 (es) | Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer (divisional sol 201801470) | |
AR114911A1 (es) | Conjugados peptídicos de tlr7 | |
TR201721700A2 (tr) | Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari | |
EA202090236A1 (ru) | Иммуногенные композиции senecavirus a и способы с ними | |
AR108879A1 (es) | Dispositivo para la esterilización de bolsas flexibles mediante irradiación por haz de electrones y procedimiento de esterilización de las mismas | |
AR117401A1 (es) | Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y métodos de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |